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Abstract 
IκB kinase subunit epsilon (IKKε), a key component of NFκB and interferon signalling, has 
been identified as a breast cancer oncogene. Here we report that the IKKε/TBK1 axis plays a 
role in the initiation and progression of breast cancer osteolytic metastasis. Cancer-specific 
knockdown of IKKε in the human MDA-MB-231-BT cells and treatment with the verified 
IKKε/TBK1 inhibitor Amlexanox reduced skeletal tumour growth and osteolysis in mice. In 
addition, combined administration of Amlexanox with Docetaxel reduced mammary tumour 
growth of syngeneic 4T1 cells, inhibited metastases and improved survival in mice after 
removal of the primary tumour. Functional and mechanistic studies in breast cancer cells, 
osteoclasts and osteoblasts revealed that IKK inhibition reduces the ability of breast cancer 
cells to grow, move and enhance osteoclastogenesis by engaging both IRF and NFκB 
signalling pathways. Thus, therapeutic targeting of the IKK/TBK1 axis may be of value in 
the treatment of advanced triple negative breast cancer.  
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Introduction 
The nuclear factor-B (NFB) signaling is implicated in inflammation and cancer[1-5]. IκB 
kinase subunit epsilon (IKKε), a key component of NFκB signalling, has been identified as a 
breast cancer oncogene[6]. A number of studies have shown that IKK is overexpressed in 
mammary breast tumours and various human breast cancer cell lines[6, 7], and its inhibition 
reduced the development of primary breast cancer in mice[8]. IKK has also been found to 
contribute to Tamoxifen resistance in oestrogen receptor positive (ER+) breast cancers[9]. 
Binding of IKK to the TANK-binding kinase 1 (TBK1) leads to the activation of NFB, 
interferon regulatory factor (IRF) signalling pathway[10, 11] as well as various cancer-
driving factors including, protein kinase B (Akt), tumour necrosis factor receptor (TNFR)-
associated factor 2 (TRAF2), and inhibition of tumour suppressors such as cylindramatosis 
tumour suppressor (CYLD) and Forkhead box O 3a (FoxO3a)[9-15]. Although the 
mechanisms through which IKK contributes to cellular transformation and primary tumour 
growth have been established[6], the role of IKK in breast cancer metastasis is not fully 
understood.  
Breast cancer cells preferentially metastasise to bone and skeletal related events are 
diagnosed in approximately 70% of advanced breast cancer cases[16]. NFB activation 
enhances excessive osteoclastic activity and causes bone loss, and various studies have 
implicated IKK in bone loss associated with oestrogen deficiency, rheumatoid arthritis and 
Paget’s disease[17-20]. However, the role of IKK in excessive bone loss associated with 
metastatic breast cancer has not been investigated. Encouraged by a recent report that 
pharmacological inhibition of IKKε, using the verified IKKε/TBK1 inhibitor Amlexanox[21], 
inhibited bone loss in a mouse model of osteoporosis[22], we tested the effects of over-
expression/knockdown and pharmacological inhibition of IKKε on the initiation, progression 
and metastasis of breast cancer. Using mouse models of syngeneic and human breast cancer, 
we showed that cancer-specific knockdown of IKK in human MDA-MB-231 and 
administration of the IKKε/TBK1 inhibitor Amlexanox in immune-competent mice 
inoculated with syngeneic 4T1 cells inhibited skeletal tumour burden and reduced osteolytic 
bone damage. Administration of Amlexanox alone in mice reduced the growth of the 
syngeneic 4T1 breast cancer cells in the mammary fat pads and it significantly enhanced the 
anti-tumour and anti-metastatic properties of the FDA-approved Docetaxel[23] in mice after 
removal of the primary tumour. Collectively, these findings suggest that, due to the combined 
anti-tumour and anti-resorptive effects, IKKε inhibitors, alone and in combination with 
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chemotherapeutic agents, may be of value in the treatment of skeletal and non-skeletal 
complications associated with advanced triple negative breast cancer. 
Materials and Methods 
Reagents 
The IKKε/TBK1 inhibitor Amlexanox was purchased from Abcam (Cambridge, UK). 
Parental MDA-MB-231, 4T1, Saos-2 osteoblast-like cells and mouse RAW 264.7 
macrophages-like cells were purchased from ATCC (Manassas, VA). The human triple 
negative bone tropic MDA-MB-231 were generated by Dr Nadia Rucci at the Univeristy of 
L’Aquila, Italy. Single cell clones of MDA-MB-231 were expanded and injected in to the left 
ventricle of 4-week-old female BALB/c-nu/nu mice a clone that generated bone only lesions 
with significant osteolysis in 8-weeks was used.[24-26]. Murine 4T1-luc2 cells were a kind 
gift from Dr. Munitta Muthana (Sheffield, UK) and were transfected to express Luciferase. 
Tissue culture medium (DMEM and alpha-MEM) was obtained from ThermoFisher 
(Leiceistershire, UK). All primary antibodies were obtained from Cell Signalling Technology 
(MA, USA) excluding rabbit anti-actin, which was purchased from Sigma-Aldrich (Dorset, 
UK). Mouse macrophage colony stimulating factor (M-CSF) was obtained from R&D 
Patrick Mollat (Galapagos SASU, France).
 
Cell lines and conditioned medium 
Human MDA-MB-231 breast cancer cells, Saos-2 osteoblast-like cells, mouse 4T1 breast 
cancer and RAW.267 macrophage-like cells were cultured in a standard D-MEM 
supplemented with 10% fetal calf serum (FCS), glutamine (2mM), penicillin (100U/ml), and 
streptomycin (100µg/ml). Human MCF-7, T47D, SK-BR-3, ZR-75-1 were cultured in a 
standard RPMI supplemented with 10% fetal calf serum (FCS), glutamine (2mM), penicillin 
(100U/ml), and streptomycin (100µg/ml).  
Lentiviral infection and generation of stable cell lines 
In order to generate IKKε-shRNA expressing lentivirus, HEK 293T-packaging cells  were 
transfected with the 5 μg pLKO.1 lentiviral vector (empty or containing IKKε-shRNA 
[TRCN-735, -736](Dharmacon)), psPAX2 vector, pCMV-VSV-G vector and 40 μl 
polyethylenimine, Lentiviral supernatant and polybrene (5 µg/ml; Sigma-Aldrich Dorset, 
UK) were were incubated with the MDA-MB-231-BT cells. Cells were selected with 1 µg/ml 
puromycin. To generate IKK overexpressing cells, a lentiviral delivered CRISPR activation 
system was used (Santa-Cruz Biotechnology) and cells were transected according to 
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manufacturer’s instructions.. The transfected MDA-MB-231 cells were maintained in 
selection for at least two passages until knockdown/overexpression was confirmed via 
western blotting. 
Small RNA interference 
Human MDA-MB-231-BT cells were transfected with siRNA (5 nM) using Dharmafect 1 
reagent (Dharmacon, CO, USA), according to the manufacturer’s instructions. A pool of four 
annealed double – stranded RNA oligonucleotides against TBK1 (M-003788-02-0005), IKKβ 
(M-003503-03-0005), p65 (M-003533-02-0005), IRF3 (M-006875-02-0005) or non-targeting 
pool no. 1 (D-001206-13-05) siRNAs were purchased from Dharmacon and used according 
to the manufacturer’s instructions. The cells were cultured for 48 hours in antibiotic free 
complete medium with the transfection reagent. The efficiency of IRF3, TBK1, IKKβ and 
p65 knockdown was assessed by Western blot analysis. 
Assessment of osteoblast differentiation and bone nodule formation 
Primary osteoblasts were isolated from the calvarial bones of 2-day-old mice by sequential 
collagenase digestion as previously described[27]. Osteoblasts were maintained in standard 
alpha-MEM. For early osteoblast differentiation assays, primary osteoblasts were plated 
(7x10
3
 cells/ well). Test compounds and conditioned medium was added the following day. 
Osteoblast differentiation was measured after 48 hours.  For bone nodule assays, Saos-2 
osteoblast-like cells were seeded into 12-well and treated with L-ascorbic acid (50 µg/ml), 
breast cancer cell conditioned medium (20% v/v), compounds at stated doses. The medium 
was refreshed every 48 hours after two treatments, β-glycerophosphate (10mM) was also 
added. The cells were cultured for up to 15 days. At the end of the culture period, osteoblast 
number, differentiation and bone nodule formation were determined by the AlamarBlue 
assay, alkaline phosphatase (Alk Phos) assay and alizarin red (ALZ) staining [27, 28]. 
Assessment of osteoclast formation and activity 
Osteoclast formation was studied using RANKL and M-CSF generated human and mouse 
osteoclasts[29] or the macrophage-like cell line RAW.267. For human osteoclasts, CD14
+
 
monocytes were isolated by using positive selection beads (Miltenyi Biotec) from peripheral 
blood mononuclear cells of healthy volunteers following separation using Ficoll-Pacque. 
Following isolation, CD14
+
 monocytes were plated with 25ng/ml MCSF to generate 
macrophages. Mouse osteoclasts were generated as previously described[30]. For cultures 
involving conditioned medium, conditioned medium was prepared as previously described 
[31] and added to cultures at 10% (v/v) with M-CSF, RANKL and test compounds for up to 9 
days with medium refreshed every 48 hours. In macrophage-like RAW cell cultures, MCSF 
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was omitted.  Osteoclasts were identified using Tartrate-resistant Acid Phosphatase (TRAcP) 
staining[31].  
Assessment of cell motility 
The migration of human MDA-MB-231 cells was assessed by wound healing assay [32]. The 
confluent cell monolayer was scratched and cellular migration was assessed over time using 
time-lapse microscopy and T-scratch analysis program. . The invasive phenotype of human 
MDA-MB-231 cells was assayed using the transwell migration assay. Briefly, matrigel 
(Corning, UK) was diluted to a final concentration of 1.5mg/ml in serum-free DMEM. A 
volume of 20µl of diluted matrigel was added to 0.8 µm Transwell inserts (Corning, UK). A 
cell suspension in serum free DMEM containing 10x10
3
 cells and test compounds was added 
to each insert. Standard DMEM (500µl) was used as the chemoattractant. After 72 hours, 
invasive cells on the underside of the membrane were fixed and stained with haemotoxylin 
and eosin. Invasive cells were quantified using ImageJ.  
Western Blotting 
Western blot analysis was used to detect protein expression and phosphorylation in cultured 
bone and breast cancer cells. Briefly, cells were seeded in 12 well plates and maintained in 
standard media until confluency. Prior to stimulation with test agents or vehicle, cells were 
incubated in serum free tissue culture medium 16 hours. Test agents or vehicle were prepared 
in serum free media and were then added for the desired period of time.  Cells were lysed  
and protein amount was quantified as previously described [33]. Total protein 50-100µg was 
resolved by SDS-PAGE on 12% polyacrylamide SDS gels, transferred onto PVDF 
membranes (BioRAD, UK) and immunoblotted with appropriate antibodies according to 
manufacturer’s instructions, using horseradish peroxidase-conjugated secondary antibody 
(Jackson labs, UK), and then visualised using chemiluminescence (Amersham, UK) on a 
Biorad ChemiDocMP imaging system. 
Measurement of levels of tumour-derived factors 
Level of tumour-derived factors in conditioned medium from human MDA-MB-231 breast 
cancer cells was determined by Proteome Profiler Human XL Cytokine Array Kit (ARY022, 
R&D Systems, Abingdon, UK), according to the manufacturer’s instructions. 
Animal experiments 
All experimental protocols were approved by the Ethics Committee at the University of 
Edinburgh and Sheffield and were conducted in accordance with the UK Home Office 
regulations.  
Intra-tibial injection in mice 
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The effects of cancer-specific inhibition and pharmacological inhibition of IKKε on skeletal 
tumour growth and osteolysis were investigated through intra-tibial injection of either human 
MDA-MB-231 or syngeneic 4T1 breast cancer cells. Briefly, 7 four week‐old female 
BALB/c‐nu/nu athymic mice were randomly allocated in groups received intra-tibial 
injection of human MDA-MB-231-BT IKKε-shRNA or IKKε-mock (4×103 cells) in the left 
tibia.  In the second intra-tibial experiment, 14 female BALB/c 10-week-old mice received 
intra-tibial injection of mouse 4T1 breast cancer cells (4×10
3
 cells) in the left leg or a sham 
injection of PBS into their right leg.  Animals were sacrificed after 21 days (MDA-MB-231) 
or 14 days (4T1). Animals were divided into two groups and received intraperitoneal 
injection of either vehicle (PBS) or Amlexanox (20mg/kg/daily). Following sacrifice, bones 
were analyzed by micro–computed tomography (microCT, Skyscan 1172 scanner). Skeletal 
tumor growth was measured on 2D microCT images using Image J and results were 
expressed as a percentage of total metaphyseal area (4T1) or on H&E stained sections using 
the OsteoMeasure software at 10x magnification.  
Intracardiac injection of murine 4T1 breast cancer cells 
We studied the effects of treatment with Amlexanox on the formation of bone metastasis and 
following intracardiac injection of syngeneic mouse breast cancer cells. Briefly, 8 week‐old 
female BALB/c mice were randomly allocated into groups, anesthetized and single-cell 
suspension of 1 × 105 4T1-Luc2 cells /100 µL PBS was injected into the left cardiac ventricle. 
The following day mice were divided in to groups (8 mice per group) and treated with either 
daily i.p. injection of vehicle (5% DMSO in PBS) or Amlexanox (35 mg/kg/day). Animals 
were monitored daily for cachexia (evaluated by body weight) and behavior. Bone metastases 
were monitored tri-weekly using the IVIS system and animals were sacrificed by cervical 
dislocation on day 11.  
Orthotopic injection of murine 4T1 breast cancer cells 
We studied the effects of treatment with Amlexanox, Docetaxel or a combination treatment 
on primary tumour growth of 4T1-Luc2 after orthotopic injection. Briefly, 8 week‐old female 
BALB/c mice were randomly allocated into groups and anesthetized. 4T1-luc2 (10x10
6
/ml) 
were re-suspended in 60% PBS, 39% growth factor reduced matrigel (Corning) and 1% 
trypan blue (Sigma Aldrich). A volume of 100µl of the cell suspension was injected into the 
fat pad of both the left and right inguinal breast (10 mice per group). Animals were monitored 
daily for cachexia (evaluated by body weight) and behavior. The size of each tumour was 
measured externally three times a week by measuring their two axes using a caliper and 
 8 
applying the formula of the volume of a sphere [4/3πr3 where r is the mean of the two axes]. 
Once tumour volume had reached the maximum volume of 1cm
3
, the tumours were resected. 
The development of metastases was monitored biweekly using the IVIS system. The primary 
tumours and the lungs, brain, spleen and hind limbs of the animals were removed and ex vivo 
IVIS imaging was performed before formalin fixation. 
Analysis of clinical data 
Retrospective analysis of IKK and TBK1 expression with respect to primary tumour growth 
and bone relapse was conducted using published cohorts of data The NKI295 dataset was 
chosen to assess the association of IKKbone metastasis,which did not initially probe for 
TBK1 expressionThe CB560 dataset was used for analysis of TBK1 association with bone 
metastasis. Exhaustive survival analysis was performed by considering all possible cut-
points using the survivALL package.  P values were derived from Wilcoxon test and were 
two-tailed.  
Statistical Analysis 
Results were reported as mean ± standard deviation (SD) unless otherwise stated. A p-value 
value of 0.05 or below was considered statistically significant. All statistical analyses carried 
out between two groups were students T-test and between three groups analysis of variance 
(ANOVA) was used. All tests were conducted in GraphPad prism 7.0 or Statistical analyses 
were performed using IBM (Armonk, NY, USA) SPSS Statistics, for windows. The 
concentration that produced 50%of response IC50 was calculated using GraphPad Prism 7 for 
Windows. 
Results 
IKKε inhibition reduces breast cancer cell growth in vitro and in vivo 
Previous studies have implicated that IKKε in breast cancer initiation and bone disease[6, 17-
20]. In our studies, we have observed that IKKε expression is upregulated in highly 
metastatic human triple-negative breast cancer cell lines including MDA-MB-231, when 
compared to hormone-sensitive MCF7 and their non-transformed MCF10 control (Fig. S1A). 
With this in mind and the observation that TBK1 expression is associated with higher risk for 
bone metastasis (Fig. S2), we tested the effects of the verified IKKε/TBK1 inhibitor 
Amlexanox on a panel on the viability of a panel of ER+ and ER- breast cancer cell lines with 
different metastatic abilities to metastasise to the skeleton. As shown in Table 1, Amlexanox 
(0 – 100M) significantly reduced the viability of breast cancer cells, however the ER- breast 
cancer cell cohort had a significantly lower IC50 value. In view of this, we stably knocked 
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down and over-expressed IKKε in the sub-clone MDA-MB-231-BT (Fig. S3), and assessed 
the growth and metastatic behaviour of these cells in vitro and in vivo. As shown in Figure 1, 
over-expression of IKKε in MDA-MB-231-BT enhanced cell migration within 6 hours, 
invasion within 48 hours and growth with 72 hours, whereas knockdown and 
pharmacological inhibition of IKKε using the IKKε/TBK1 inhibitor Amlexanox were 
inhibitory (Fig. 1A-E). In vivo, both immuno-deficient mice inoculated with MDA-MB-231-
BT cells deficient in IKKε and immuno-competent mice which received the IKKε/TBK1 
inhibitor Amlexanox after inoculation with the syngeneic 4T1 cells exhibited significant 
reduction in the growth of tumour cells in the tibial metaphysis of mice (Fig. 1F). 
IKKε inhibition reduced breast cancer-induced osteolysis in vivo 
To test if IKKε is implicated in the ability of cells to cause osteolytic bone loss, we assessed 
bone volume and architecture in mice after intra-tibial injection of breast cancer cells. 
Detailed micro-computed tomography (microCT) analysis of bone volume at the tibial 
metaphysis of immuno-deficient mice inoculated with human MDA-MB-231-BT cells 
deficient in IKKε (Fig. 2A) showed significant increase in total bone volume (BV/TV; Fig. 
2B), increased trabecular connectivity (Conn, Fig. 2C) and reduced porosity (Po, Fig. 2D) yet 
had no effect on trabecular thickness (Tb.Th, Fig 2E). Histomorphometric analysis of 
histological samples from these mice demonstrated that cancer-specific knockdown of IKKε 
reduced osteoclast number (Fig. 2F), but had no effect on the number of osteoblasts (Fig. 
2G). Using the syngeneic model of 4T1-BT (Fig. 3A), we went on to demonstrate that 
treatment of immuno-component mice with the IKKε/TBK1 inhibitor Amlexanox modestly 
but significantly increased total bone volume (BV/TV; Fig. 3B) and enhanced trabecular 
thickness (Fig. 3C), reduced bone porosity (Fig. 3D) connectivity (Fig. 3E). 
Histomorphometric analysis of histological samples from these mice revealed that 
administration of the IKKε/TBK1 inhibitor Amlexanox reduced osteoclast number (Fig. 3F) 
without affecting osteoblast number (Fig. 3G). Similar effects on osteoclast and osteoblast 
differentiation were obtained in in vitro experiments using RANKL-stimulated osteoclasts 
and calvarial osteoblasts. As shown in Figure 4, over-expression of IKKε significantly 
increased the ability of in the MDA-MB-231-BT to enhance RANKL-induced osteoclast 
formation, whereas exposure to the IKKε/TBK1 inhibitor Amlexanox inhibited this effect 
(Fig. 4A, left panels). Consistently, exposure of osteoclast precursors to MDA-MB-231-BT 
(Fig. S4) or conditioned medium from MDA-MB-231-BT deficient in IKKε or treated with 
Amlexanox reduced RANKL-induced osteoclast formation in vitro (Fig. 4B-C). Exposure of 
calvarial osteoblasts to conditioned medium from MDA-MB-231-BT deficient in IKKε or 
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treated with Amlexanox had no effects on alkaline phosphatase activity (Fig. 4D) or bone 
nodule formation (Fig. 4E-F). These results demonstrate that expression of IKKε by breast 
cancer cells contributes to their osteolytic potential without affecting osteoblast number. 
IKKε regulates MDA-MB-231 behaviour by IRF3/NFκB activation 
IRF3/NFκB signalling plays a key role in IKKε/TBK1 activity in primary cancer cells [6, 34]. 
To examine whether IRF3/NFκB signalling contributes to the osteotropic behaviour of breast 
cancer cells in our models, we knocked down, TBK1, IKKβ, p65 or IRF3 in MDA-MB-231-
BT cells overexpressing IKKε (Fig. S5A-B), and we studied the metastatic and osteolytic 
behaviour of these cells in vitro. First, we observed that knockdown of TBK1, IKKβ, IRF3 or 
p65 in these cells significantly inhibited IKKε-driven cell migration (Fig. 5A) and reduced 
the ability of these cells to support RANKL-induced osteoclast formation in bone marrow 
cell line cultures (Fig. 5B). In light of this, analysis of protein level of human cytokines and 
chemokines in conditioned medium revealed that IKKε overexpression in the MDA-MB-231-
BT cells is associated with upregulation by greater than 2-fold of 11 secreted proteins 
(Fig. 5C). The identified proteins are common tumour-derived factors that have previously 
been found to be involved in the regulation of inflammation, angiogenesis, and tumorigenesis 
and osteolysis including lipocalin-2 (LPN2) and interleukins –1 (IL-1), -6 (IL-6) and -8 (IL-
8) (Fig. 5D), Furthermore, only silencing of p65 reduced the expression of these proteins to 
below basal levels of MDA-MB-231 mock cells, implicating the NFB signalling pathway in 
the regulation of IKK/TBK1 driven osteotropic behaviour of the model described. 
Consistent with this, we also show that knockdown of IKKβ or p65 – but not IRF3 or TBK1 - 
reduced the viability of MDA-MB-231 cells over-expressing IKKε (Fig. S5C).   
Amlexanox reduces breast cancer osteolytic metastasis 
Previous research has implicated IKKε in the initiation of primary tumour growth[6, 8]. 
However, the effect of IKKε inhibition on the initiation and development of breast cancer 
osteolytic metastasis has not been investigated. As shown in Figure 6, administration of 
Amlexanox (35mg/kg/day) in mice reduced the homing and growth of the syngeneic 4T1 
breast cancer cells as evidenced by in vivo bioluminescent imaging (Fig. 6A-C).  
Combination of Amlexanox and Docetaxel reduces the growth and metastasis of 
mammary tumour cells 
Previous studies have implicated members of the NFκB pathway in increased resistance to 
various chemotherapies[9, 35-37]. Of all the chemotherapeutic agents tested (Docetaxel, 
Cyclophosphamide, Doxorubicin, Rapamycin, 5-Fluorouracil and Tamoxifen; data not 
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shown), only Docetaxel significantly enhanced IKKε expression in parental MDA-MB-231 
breast cancer cells (Fig. S6A) and treatment of these cells with Amlexanox enhanced the anti-
tumour effects of Docetaxel by up to 50% (Fig. S6B-D, p<0.05). With this in mind, we next 
sought to determine whether Amlexanox sensitizes the parental and syngeneic 4T1 breast 
cancer cells to Docetaxel in mammary orthotopic mouse model. As shown in Figure 6D, 
combined administration of Amlexanox (35mg/kg/day) and Docetaxel (15mg/kg/week) 
reduced mammary tumour growth (59.7%, p<0.001) in mice inoculated with the 4T1-luc2 
cells. After removal of tumours, Amlexanox and Docetaxel reduced incidence of overt 
metastases (Fig. 7A-C) and improved survival (Fig. 7D, 1.82 fold, p<0.005) (p<0.05), when 
compared to vehicle or individual treatments. 
Discussion   
Although previous studies have implicated both the canonical and non-canonical IKK/NFB 
pathways in breast cancer[38, 39], IKKε is the only IKK family member that has been 
deemed a breast cancer oncogene[6]. Here we provide evidence for a previously unknown 
role of IKKε in the regulation of the initiation and progression of breast cancer osteolytic 
metastasis. The evidence for this comes from the experiments that showed that cancer-
specific knockdown of IKKε in the human triple negative MDA-MB-231 breast cancer cells 
reduced cell growth and motility in vitro and both cancer-specific knockdown and 
pharmacological inhibition of IKKε suppressed the growth of human MDA-MB-231 and 
mouse 4T1 cells in the long bones of mice, thereby indicating an inhibitory effects on skeletal 
tumour burden.  
Previous studies reported that the activation of IKK/NFB signalling plays a critical role in 
breast cancer bone metastasis and osteolysis[39-42]. Our current data compliment these 
studies and demonstrate that systemic administration of the pharmacological inhibitor of 
IKKε/TBK1 suppressed the ability of the syngeneic 4T1 breast cancer cells to home, grow 
and to enhance osteoclast number and osteolysis in mice. These data also expand on previous 
observations and suggest that the osteoprotective effect associated with IKKε/TBK1 
inhibition is mediated not only by the effects on breast cancer cells but also by inhibition of 
IKKε/TBK1 in bone cells of the tumour microenvironment in the skeleton. Evidence for this 
comes from the in vivo observations that pharmacological inhibition of IKKε/TBK1 reduced 
osteoclast number and the in vitro data that showed that IKKε/TBK1 in either breast cancer 
cells or osteoclast precursors significantly reduced the ability to support osteoclast formation.  
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Pro-inflammatory mediators secreted by breast cancer and bone cells in the tumour 
microenvironment in the skeleton are essential for the development of breast cancer related 
bone disease[1-5, 43]. The activation of NFκB and IRF signal transduction pathways by 
tumour-derived factors is know to regulate osteoclastogenesis, skeletal tumour growth and 
bone remodelling and bone loss[9-15, 17, 44]. Mechanistic studies in human breast cancer 
cell and osteoclast cultures revealed that the IKKε-driven pro-migratory and pro-osteolytic 
capacities in our models were abrogated by siRNA-mediated knockdown of TBK1, IRF3 or 
NFκB, consistent with the involvement of both the IRF and NFκB signalling pathways[10, 
11]. Collectively, these results provide a novel insight into the role of IKKε/TBK1 signalling 
in the reciprocal interaction between bone and breast cancer cells in the skeleton. When 
combined with previous studies that reported the role of IKKε in breast cancer initiation and 
development[8, 9] – these results implicate cancer and bone-cell autonomous expression of 
IKKε in primary and secondary breast cancer to bone. 
The IKKε/TBK1 inhibitor Amlexanox enhanced the cytotoxic effects of a panel of 
chemotherapeutic agents including Docetaxel (Fig. S6 and data not shown), and continuous 
exposure of human breast cancer cells to Docetaxel enhanced IKKε. Consistent with this we 
have demonstrated that combined administration of Amlexanox and Docetaxel exerted a 
synergistic effect characterised by significant reduction of primary tumour growth, overt 
metastases coupled with approximately a 2-fold improvement in metastasis-free survival 
when compared to vehicle or either treatment as a single-agent. It is important to note that 
Amlexanox - as a single agent – also reduced primary tumour growth in these experiments 
but it had no effect on overt metastases or enhance metastasis-free survival of mice following 
removal of the primary tumour. Our interpretation of these results is that IKKε/TBK1 
inhibition is sufficient to reduce mammary and skeletal tumour growth and osteolysis but 
failed to reduce general metastasis in the 4T1 models described.  
Although the work presented here indicates that IKKε inhibition may be of value in the 
reduction of breast cancer-induced osteolysis, our studies were restricted to the MDA-MB-
231 and 4T1 in vivo models. It is also important to note that administration of Amlexanox 
alone or in combination with Docetaxel had no significant effect on the frequency of bone 
metastasis (Fig. 5C) and the expression of TBK1 – but not IKKε – is associated with higher 
risk for bone metastasis in the dataset tested (Fig. S2). Therefore, further studies will be 
required to determine if inhibition of IKKE, TBK1 or both are effective in reducing the 
development and progression of bone metastases.  
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In summary, the results of the present study demonstrate that IKKε plays an essential role in 
the regulation of primary and skeletal tumour growth, osteolysis and enhanced bone cell 
activity associated with advanced breast cancer (Figure S7). These results offer new insight 
into the role of the NFB and IRF signalling pathways in the crosstalk between breast cancer 
cells and bone cells of the tumour microenvironment, and provide evidence to show that 
disruption of IKKε/TBK1, alone or in combination with clinically relevant chemotherapies 
such as Taxanes, may have potential therapeutic efficacy in advanced triple negative breast 
cancer. The potential benefit of combined administration of IKKε/TBK1 inhibitors and anti-
resorptive agents such as bisphosphonates and Denosumab in models of in breast cancer bone 
metastasis needs to be explored. For that, further in vivo studies are warranted. 
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Figures and legends 
Figure 1. IKKε inhibition inhibited breast cancer cell growth in vitro and in vivo. 
A-B. In vitro cell growth of human MDA-MB-231 (MDA-MB-231-BT) cells 
overexpressing (IKKεOE) and deficient in (IKKeKD1 and KD2) IKKε or their mock 
control in the presence and absence of the IKKε/TBK1 inhibitor Amlexanox (10 – 
100M) after 72 hours as assessed by AlamarBlue assay. B-C. In vitro cell migration 
of MDA-MB-231-BT described in panel A after 6 hours as assessed by wound 
healing assay. Representative photomicrographs from the experiment described are 
shown in panel B. D-E. In vitro cell invasion of the human MDA-MB-231-BT cells 
described in panel A after 72 hours as assessed by Transwell invasion assay. 
Representative photomicrographs from the experiment are shown in panel D. F. In 
vivo tumour growth in bone (% tumour area/bone area) after intra-tibial injection of 
human MDA-MB-231 (left panel) cells deficient in IKKε (IKKεKD2) or their mock 
control into nu/nu BALB/c mice or mouse 4T1-BT (right panel) cells into immuno-
component BALB/c mice treated with the IKKε/TBK1 inhibitor Amlexanox (AmX, 
20mg/kg/daily) (n = 7 group, 14 days). **p < 0.01 from vehicle or mock control. 
Figure 2. Cancer-specific IKKε inhibition reduced breast cancer-induced 
osteolysis in nude mice. A. Graphic representation of intra-tibial injection of human 
MDA-MB-231 deficient in IKKε (IKKeKD2) or their mock control into nu/nu 
BALB/c mice (n = 5 mock and n=7 IKKεKD, 21 days). B-D. In vivo total trabecular 
bone volume (B, BV/TV, %), trabecular connectivity (C, Tb.conn, m) and porosity 
(D, Po, %) and thickness (E. Tb. Th, m) in the nu/nu BALB/c mice described in 
panel A. F-G. In vivo osteoclastogenesis (E) and osteoblast number (G) in mice from 
the experiment described in panels A - D. *p < 0.05 **p < 0.01 from vehicle. 
Figure 3. Amlexanox reduced breast cancer-induced osteoclast formation and 
osteolysis in immuno-competent mice. A. Graphic representation of intra-tibial 
injection of 4T1-BT cells in immuno-component BALB/c mice treated with vehicle or 
the IKKε/TBK1 inhibitor Amlexanox (AmX, 20mg/kg/daily) (n = 7, 12 days). B-E. In 
vivo total trabecular bone volume (B, BV/TV, %), trabecular connectivity (C, 
Tb.conn, µm) and porosity (D, Po, %) and thickness (E, Tb.Th, µm) in mice from the 
experiments described in panel A. F-G. In vivo osteoclastogenesis (F) and osteoblast 
number (G) in mice from the experiment described in panels A - D. **p < 0.01 from 
vehicle. 
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Figure 4. IKKε regulates behaviour of breast cancer cells. A-C. In vitro 
osteoclastogenesis of RANKL-stimulated human monocytes (A and B left) or mouse 
bone marrow cells (B right) after exposure to conditioned medium (20% v/v) from 
human MDA-MB-231 (MDA-MB-231-BT) cells overexpressing (IKKεOE) and 
deficient (IKKε KD1 and KD2) in IKKε or their control (MDA-mock) in the presence 
and absence of the IKKε/TBK1 inhibitor (10µM) Amlexanox after 120 hours as 
assessed by TRAcP staining assay. Representative photomicrographs of 
multinucleated TRAcP positive osteoclasts from the experiment described are shown 
in panel B left. D. In vitro differentiation of primary calvarial osteoblasts after 
exposure to conditioned medium (20% v/v) from human MDA-MB-231 (MDA-MB-
231-BT) cells overexpressing (IKKεOE) and deficient (IKKεKD1 and KD2) in IKKe 
or their control (MDA-mock) in the presence and absence of the IKKε/TBK1 
inhibitor (10µM) Amlexanox after 72 hours as assessed by alkaline phosphatase 
(ALP) colourimetric assay. E-F. In vitro bone nodule formation in human osteoblast-
like cells Saos2 after exposure to conditioned medium (20% v/v) from human MDA-
MB-231 (MDA-MB-231-BT) cells in the presence and absence of the IKKε/TBK1 
inhibitor (0.01 - 10µM) Amlexanox after 12 days as assessed by Alazarin Red 
staining assay. Representative photomicrographs of bone nodules from the experiment 
described are shown in panel F. **p < 0.01 from vehicle or mock control, +p< 0.05 
from MDA-MB-231-BT-IKKεOE. 
Figure 5. IKKε regulates osteotropic behaviour of MDA-MB-231 by IRF3/NFκB 
activation A.  (Left) In vitro cell migration of human MDA-MB-231 (MDA-MB-
231-BT) cells overexpressing (IKKεOE) or the mock control following transfection 
with targeting IRF3, TBK1, IKKβ or p65 or a scrambled control siRNA pools (Scrsi) 
compared to the non-transfected controls after 8 hours as assessed by the wound 
healing assay.  B In vitro osteoclastogenesis of RANKL-stimulated mouse 
macrophage-like RAW cells after exposure to conditioned medium (20% v/v) from 
human MDA-MB-231 (MDA-MB-231-BT) cells overexpressing (IKKεOE) or the 
mock control following transfection with targeting IRF3, TBK1, IKKβ or p65 or a 
scrambled control siRNA pool (Scr
si
) compared to the non-transfected controls after 
120 hours as assessed by TRAcP staining assay. C Catalogue of differentially 
expressed inflammatory mediators in the conditioned medium from MDA-MB-231 
IKKεOE transiently transfected with scrambled siRNA (Scr), IRF3 targeting siRNA 
(IRF3) or p65 targeting siRNA (p65) compared to MDA-MB-231 Mock cells 
transiently transfected with scrambled siRNA assessed by Proteome Profiler Human 
XL Cytokine Array Kit. D Photomicrographs of differentially expressed cytokines 
assessed by Proteome Profiler Human XL Cytokine Array Kit.  *p < 0.05, **p < 0.01 
from scrambled siRNA treated Mock control MDA-MB-231-BT, 
#
p < 0.05, 
##
p < 0.01 
###
p<0.001 from scrambled treated MDA-MB-231-BT-IKKεOE. 
Figure 6. Amlexanox reduces primary and skeletal tumour growth in mice. A. 
Graphic representation of intracardiac injection of parental 4T1 cells (4T1-luc2) in 
immuno-component BALB/c mice treated with vehicle (PBS), the IKKε/TBK1 
inhibitor Amlexanox (35mg/kg/daily). B. Combined in vivo hind limb tumour growth 
in mice from the experiments described in panel A after 11 days post inoculation of 
cells. C. Representative real-time imaging of bioluminescence of metastatic tumours 
from the experiment described are shown. D. Graphic representation of orthotopic 
injection of parental 4T1 cells (4T1-luc) in immuno-component BALB/c mice treated 
with vehicle, the IKKε/TBK1 inhibitor Amlexanox (AmX, 35mg/kg/daily), Docetaxel 
(Doc, 15mg/kg/1-time-weekly) or the combination of two agents (n = 10 per group, 
up to 35 days). E. In vivo mammary tumour growth in mice from the experiments 
described in panel F. Real-time imaging of bioluminescence of tumours (bottom) 
from the experiment described are shown in panels D-E. *p < 0.05 from vehicle and 
+p < 0.01 from individual treatment. 
Figure 7. Combination of Amlexanox and Docetaxel reduces overt metastases of 
parental 4T1 in immuno-competent mice. A. Quantification of overt metastasis in 
mice from the experiments described in Figure 6 panel D-E. B Photomicrographs of 
real-time bioluminescence imaging following the removal of primary metastasis on 
day 27 since mammary fat pad inoculation. Representative photomicrographs of 
metastasis from the experiment described are shown in panel C. D. Frequency of 
metastases in excised organs from the experiments described in panels A – C. E. 
Survival of mice from the experiment described in panels A-C. *p<0.05 **p < 0.01 
from vehicle, # p < 0.05 compared to Amlexanox treated group, $ p < 0.05 compared 
to Docetaxel treated group 
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 Tables 
Table 1. Effects of Amlexanox on the viability of a panel of ER+ and ER- breast cancer cell 
lines with different metastatic abilities to metastasise to the skeleton. 
 
Receptor Status Breast Cancer Cell line IC50 (μM ±SD) 
ER+ 
MCF7 159.6 ± 1.4 
T47D 330.4 ± 1.6 
ZR-75-1 142.6 ± 1.3 
ER- 
SKBR3 98.9 ± 1.2 
MDA-MB-468 101.9 ± 1.2 
MDA-MB-231 108.1 ± 1.1 
MDA-MB-BT1 73.4 ± 2.5 
4T1-Luc2 30.0 ± 1.1 
 
Cell viability was measured after 48 hour of continuous exposure to Amlexanox by AlamarBlue 
assay. Calculation of half maximal inhibitory concentrations (IC50) has been performed as 
described under “Materials and Methods”. Values are mean ± SD and are obtained from 3 
independent experiments. BT denotes osteotropic cells. 
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